Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome

NCT ID: NCT02050607

Last Updated: 2020-07-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity is associated with changes in the composition and metabolic function of the gut microbiota. Fecal microbiota transplantation (FMT), also known as "fecal bacteriotherapy" or "fecal infusion", refers to the process of injecting a liquid suspension of stool from a healthy donor into the gastrointestinal (GI) tract of a patient to cure a specific disease. However, since the recently established concept of human gut microbiome and its significant role in health and disease has caught on in the medical scientific world, this procedure has gained a great pathophysiological strength, meaning not only the simple infusion of stools, but the transplantation of a healthy gut microbiota in a patient with a disrupted one. In a recent dutch experience, FMT from lean donors was able to increase the insulin sensitivity in patients with metabolic syndrome.

Our primary aim is to evaluate if FMT from lean healthy donors, in association to lifestyle changes, is able to reduce insulin-resistance more than lifestyle changes alone in patients with metabolic syndrome.

All the patients with metabolic syndrome will receive lifestyle counselling (1400 kilocalories diet and physical activity encouragement), than will be randomized to FMT from healthy lean donors by upper endoscopy (group A) or no treatment (group B)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Control group

Group Type NO_INTERVENTION

No interventions assigned to this group

Fecal microbiota transplantation

Fecal microbiota transplantation from healthy lean donors

Group Type EXPERIMENTAL

fecal microbiota transplantation from healthy lean donors

Intervention Type OTHER

fecal microbiota transplantation from healthy lean donors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fecal microbiota transplantation from healthy lean donors

fecal microbiota transplantation from healthy lean donors

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both males and females between 30 and 60 years old
* BMI\>30 and \>35 kg/m2
* Diagnosis of Metabolic Syndrome according to National Cholesterol Education Program's Adult Treatment Panel III criteria
* No ongoing therapy for diabetes, hyperlipidemia or arterial hypertension
* Signature of written informed consent

Exclusion Criteria

* recent (3 months) use of probiotic, antibiotics or other drugs
* Increase in triglycerides levels, (≥ 300 mg/dl), LDL levels (≥ 190 mg/dl, or modification of body weight (±5%) during the last 3 months
* Relevant cardiovascular diseases or kidney diseases
* Relevant gastrointestinal diseases (such as inflammatory bowel disease or celiac disease)
* Former gastrointestinal surgery
Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Catholic University of the Sacred Heart

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Giovanni Cammarota

Prof

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Catholic University of Sacred Heart - "A. Gemelli" University Hospital

Rome, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FMTandMETs-002

Identifier Type: OTHER

Identifier Source: secondary_id

FMTandMETs-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oral Fecal Transplant in Cirrhosis
NCT03152188 COMPLETED PHASE1
Fecal Microbiota Transplant for Autobrewery Syndrome
NCT06083142 RECRUITING EARLY_PHASE1
Fecal Transplant for Hepatic Encephalopathy
NCT03439982 COMPLETED PHASE1/PHASE2